Mechanisms of Gut Microbiota in Improving Metabolic Syndrome-Related Parameters Following Helicobacter pylori Eradication

What this Trial Is About

This research aims to understand how treating Helicobacter pylori infection may improve metabolic syndrome, which includes high blood sugar, cholesterol problems, and obesity. It explores whether adding probiotics or berberine to standard Helicobacter pylori treatment can better restore gut bacteria balance and enhance metabolic health. The study is a randomized controlled trial conducted by Nanjing First Hospital to clarify the gut microbiota's role in these effects. Participants are divided into three groups: one receives vonoprazan and amoxicillin dual therapy for 14 days, the second group receives the same treatment plus probiotics, and the third group receives the dual therapy plus berberine. The study includes healthy volunteers without infection or metabolic syndrome for comparison. Treatments are oral and monitored over a 14-day period, followed by assessments at one month. Before treatment, participants undergo breath tests, blood tests for glucose and cholesterol, stool analysis for gut bacteria, and body measurements. After one month, these tests are repeated to evaluate Helicobacter pylori eradication and changes in metabolic parameters. Researchers measure changes in blood sugar, cholesterol, blood pressure, waist size, and gut microbiota composition. Safety and adherence are monitored, with participants followed for the trial duration from screening to one-month follow-up.

Eradication of Helicobacter Pylori Improves Metabolic Syndrome Through Modulation of Gut Microbiota.